Radiological and clinical findings in uveal melanoma treated by plaque interventional radiotherapy (brachytherapy): Visual atlas and literature review on response assessment.
brachytherapy
interventional radiotherapy
plaque
uveal melanoma
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
23
08
2021
accepted:
03
01
2022
entrez:
2
3
2022
pubmed:
3
3
2022
medline:
3
3
2022
Statut:
ppublish
Résumé
Uveal melanoma (UM) is the most common intra-ocular tumor in Caucasian adults and may derive from melanocytes. Historically, the first therapeutic approach to treat UM has been surgical removal of the eye, with obvious consequences in terms of function, cosmesis, and psychological impact on patients. Collaborative Ocular Melanoma Study (COMS) introduced the first uniform approach to perform interventional radiotherapy (IRT - brachytherapy) procedure in a standardized way that allowed to demonstrate equivalence of IRT with enucleation in terms of overall survival. Since this milestone, several international guidelines have been issued with regard to several technical aspects of this procedure, which has become the mainstream therapy worldwide. However, nowadays, there is still a lack of consensus about the criteria to definitively assess UM response after IRT. We present a collection of paradigmatic cases treated in our institution, and then discuss in detail the latest available evidence on the topic.
Identifiants
pubmed: 35233241
doi: 10.5114/jcb.2022.113271
pii: 46344
pmc: PMC8867240
doi:
Types de publication
Journal Article
Langues
eng
Pagination
96-106Informations de copyright
Copyright © 2022 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
J Contemp Brachytherapy. 2021 Apr;13(2):117-125
pubmed: 33897784
Br J Ophthalmol. 1990 Jun;74(6):359-62
pubmed: 2378844
Br J Ophthalmol. 2004 Jul;88(7):892-5
pubmed: 15205232
J Contemp Brachytherapy. 2021 Jun;13(3):358-364
pubmed: 34122577
Klin Monbl Augenheilkd. 2003 Dec;220(12):853-60
pubmed: 14704943
Clin Oncol (R Coll Radiol). 2016 Mar;28(3):198-203
pubmed: 26385821
J Contemp Brachytherapy. 2019 Feb;11(1):54-60
pubmed: 30911311
J Contemp Brachytherapy. 2020 Feb;12(1):84-89
pubmed: 32190074
Ophthalmology. 1984 Dec;91(12):1716-9
pubmed: 6522001
Sci Rep. 2020 Jul 9;10(1):11297
pubmed: 32647177
Melanoma Res. 2019 Jun;29(3):295-300
pubmed: 30383721
Ophthalmologica. 2003 Sep-Oct;217(5):315-9
pubmed: 12913319
Ophthalmology. 2002 Jun;109(6):1137-41
pubmed: 12045056
Graefes Arch Clin Exp Ophthalmol. 2016 Jul;254(7):1371-8
pubmed: 26907932
Arch Ophthalmol. 2006 Dec;124(12):1684-93
pubmed: 17159027
Ophthalmology. 2018 May;125(5):755-756
pubmed: 29681297
Ocul Oncol Pathol. 2017 Jul;3(2):87-94
pubmed: 28868276
J Contemp Brachytherapy. 2021 Apr;13(2):126-134
pubmed: 33897785
Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2612-23
pubmed: 25813993
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Retina. 2008 Oct;28(9):1289-95
pubmed: 18628721
BMC Ophthalmol. 2021 Mar 16;21(1):137
pubmed: 33726696
Front Oncol. 2020 May 19;10:825
pubmed: 32509587
Ophthalmology. 2017 Oct;124(10):1532-1539
pubmed: 28549517
Brachytherapy. 2014 Jan-Feb;13(1):1-14
pubmed: 24373763
J Contemp Brachytherapy. 2017 Jun;9(3):287-295
pubmed: 28725254
Ophthalmology. 2018 May;125(5):747-754
pubmed: 29499831
Clin Ophthalmol. 2017 Jan 31;11:279-289
pubmed: 28203054
Br J Ophthalmol. 1930 Apr;14(4):145-52
pubmed: 18168859
Eur J Ophthalmol. 2018 Nov;28(6):722-730
pubmed: 29788760
Graefes Arch Clin Exp Ophthalmol. 2014 Dec;252(12):2021-2
pubmed: 25212495
Middle East Afr J Ophthalmol. 2015 Jan-Mar;22(1):103-7
pubmed: 25624683
In Vivo. 2020 Jan-Feb;34(1):381-387
pubmed: 31882502
Ophthalmology. 2017 Jul;124(7):1023-1030
pubmed: 28377036